DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Vesta Lai, RN
- Phone Number: 8508 416-340-4800
- Email: vesta.lai@uhn.ca
Study Contact Backup
- Name: Yuliya Lytvyn, PhD
- Email: Julia.lytvyn@mail.utoronto.ca
Study Locations
-
-
-
Toronto, Canada
- Recruiting
- Renal Physiology Laboratory
-
Principal Investigator:
- David Cherney, MD, PhD
-
Contact:
- Vesta Lai, RN
- Phone Number: 8508 416-340-4800
- Email: vesta.lai@uhn.ca
-
Contact:
- Yuliya Lytvyn, PhD
- Email: Julia.lytvyn@mail.utoronto.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- eGFR ≥30 ml/min/1.73m2
- In patients with type 2 diabetes, HbA1c <12.0%
- Body Mass Index (BMI) 18.5-45.0 kg/m2
- Blood pressure < or = 160/100 at screening (sitting)
- Stable dose of maximally tolerated ACE inhibitor, angiotensin receptor blocker or renin inhibitor for at least 30 days
- Stable diuretic dose for at least 14 days prior to baseline study Visit
- High cardiovascular risk: an age of 50 years or more with at least one cardiovascular coexisting condition (coronary heart disease, cerebrovascular disease, peripheral vascular disease, chronic kidney disease of stage 3 or greater, or chronic heart failure of New York Heart Association class II or III) OR an age of 60 years or more with at least one cardiovascular risk factor, as determined by the investigator (microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction, or an ankle-brachial index [the ratio of the systolic blood pressure at the ankle to the systolic blood pressure in the arm] of less than 0.9).
Exclusion Criteria:
- Type 1 Diabetes
- Iodine intolerance
- Hypersensitivity or allergy to dapagliflozin
- Use of an SGLT2 inhibitor within 30 days
- Leukocyte and/or nitrite positive urinalysis that is untreated
- Severe hypoglycaemia within 1 month prior to screening
- Unstable coronary artery disease with acute coronary syndrome, percutaneous intervention or bypass surgery within 3 months
- Clinically significant valvular disease in the opinion of the investigator
- Congestive heart failure secondary to an infiltrative cardiomyopathic process (for example amyloid) or pericardial constriction
- Bariatric surgery or other surgeries that induce chronic malabsorption within 1 year;
- Anti-obesity drugs or diet regimen and unstable body weight three months prior to screening;
- Treatment with systemic corticosteroids
- Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells
- Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control
- Participation in another trial with an investigational drug within 30 days of informed consent
- Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement
- Liver disease, defined by serum levels of alanine transaminase, aspartate transaminase, or alkaline phosphatase >3 x upper limit of normal as determined during screening
- Medical history of cancer or treatment for cancer in the last five years prior to screening, aside from uncomplicated basal cell or squamous cell carcinoma;
- Unstable or rapidly progressive renal disease as per investigator judgement
- Intolerance or sensitivity to SGLT2 inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dapagliflozin Treatment Arm
Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
|
Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
|
|
Placebo Comparator: Placebo Arm
Placebo Matching Dapagliflozin Tablet for 12 weeks
|
Placebo once daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arterial stiffness
Time Frame: Acute (1 week)
|
Measured using a Sphygmocor device
|
Acute (1 week)
|
|
Arterial stiffness
Time Frame: Chronic (12 weeks)
|
Measured using a Sphygmocor device
|
Chronic (12 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glomerular filtration rate
Time Frame: Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 2 time points: acute (1 week) and chronic (12 weeks)
|
GFR
|
Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Flow mediated dilation
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
FMD
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Nitroglycerin mediated dilation
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Systolic blood pressure
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Diastolic blood pressure
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Heart rate
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Echocardiography
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Changes to systolic and diastolic function
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Non-Invasive Cardiac Output Monitoring (Measured using a NICOM device)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Cardiac output and systemic vascular resistance
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Bioimpedence spectroscopy
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measure of extracellular water
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Plasma concentration of natriuretic peptides
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Plasma concentration of the renin-angiotensin aldosterone system (RAAS) hormones
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Nitric oxide
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Fractional excretion of sodium, using lithium clearance as a surrogate for proximal tubular sodium handling
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Urinary concentration of the renin-angiotensin aldosterone system (RAAS) markers
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Urinary adenosine
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
mRNA expression of monocyte chemoattractant protein-1(MCP-1)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of intercellular adhesion molecule-1(ICAM-1)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of plasminogen activator inhibitor-1(PAI-1)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of transforming growth factor-beta (TGF-beta)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of connective tissue growth factor (CTGF)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of interleukins (IL-1beta, IL-6)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of tumour necrosis factor-alpha (TNF-alpha)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of matrix metalloproteinases 2 (MMP2)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of matrix metalloproteinases 9 (MMP9)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of advances glycation end-product (AGE)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
mRNA expression of receptor for AGE (RAGE)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Measured in urine and skin biopsy samples
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
Urinary thiobarbituric acid reactive substances (TBARS)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
|
|
Urinary 8-hydroxydeoxyguanosine (8-OHdG)
Time Frame: Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of hypoglycaemic episodes
Time Frame: Throughout study completion, an average of 12 weeks
|
Throughout study completion, an average of 12 weeks
|
|
Serious adverse events
Time Frame: Throughout study completion, an average of 12 weeks
|
Throughout study completion, an average of 12 weeks
|
|
Drug related adverse events
Time Frame: Throughout study completion, an average of 12 weeks
|
Throughout study completion, an average of 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David ZI Cherney, MD PhD FRCPC, University Health Network, Toronto General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18-5597
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.